Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections... Show more
Merck & Co., Inc. (known as MSD outside the United States and Canada) is one of the world's largest pharmaceutical companies. Investors follow MRK because the company sits at the center of oncology, vaccines, and animal health, three durable areas of global healthcare spending. Its company overview reflects a business built around blockbuster medicines, a broad research-and-development pipeline, and significant geographic reach, giving it a prominent market position among major drugmakers.
Merck traces its roots to 1891, when it was established in the United States as an affiliate of a German parent company. Today it operates as an independent, publicly traded healthcare company headquartered in Rahway, New Jersey. The business model is research-intensive: Merck invests heavily in discovering and developing new medicines, then commercializes them globally through wholesalers, retailers, hospitals, government agencies, and managed-care providers.
The company's primary revenue sources fall into two segments. The Pharmaceutical segment includes human health prescription medicines and vaccines, covering oncology, vaccines, infectious diseases, and cardiometabolic and respiratory conditions. The Animal Health segment develops and markets veterinary pharmaceuticals, vaccines, and health-management solutions for both livestock and companion animals.
Merck's most important product is Keytruda, a cancer immunotherapy that treats a wide range of tumor types. In its 2025 fiscal year, Keytruda and its follow-on subcutaneous formulation generated approximately $31.7 billion in sales, representing roughly half of the company's total revenue. Other notable products include the Gardasil family of human papillomavirus (HPV) vaccines, pediatric vaccines, and newer treatments such as Winrevair for pulmonary arterial hypertension and Ohtuvayre for chronic obstructive pulmonary disease.
Merck's investment appeal is rooted in several long-term characteristics of its financial profile. First, oncology leadership: Keytruda is one of the best-selling medicines in the world and is approved across dozens of indications, giving the company a durable position in cancer care. Second, scale and diversification: while oncology dominates, Merck's vaccines franchise and its growing animal-health business add breadth across different healthcare categories and geographies.
The company also maintains a substantial research pipeline and has used acquisitions to supplement internal innovation, helping it position newer products to carry growth as older franchises mature. Its strong cash generation and global customer base, which spans government buyers, hospitals, and distributors, further contribute to its standing among large-cap pharmaceutical peers.
Investors weighing MRK should understand several structural risks. The company's reliance on a single product is significant: Keytruda accounts for nearly half of total sales, and its key U.S. patent is expected to expire around 2028, with biosimilar competition likely to follow. A material decline in that franchise could pressure the broader business.
Merck also faces ongoing pricing and regulatory pressure, including U.S. drug-pricing reforms, international reference pricing, and government purchasing programs, which can compress margins. Vaccine demand can be volatile; Gardasil sales, for example, have been affected by inventory and demand shifts in China and Japan. Finally, as with all pharmaceutical companies, Merck carries pipeline risk, because experimental drugs can fail in clinical trials or face regulatory setbacks, as well as litigation exposure tied to its products.
For investors seeking to analyze opportunities like MRK more efficiently, Tickeron's AI Screener is an AI-powered stock and ETF discovery platform. It helps traders and investors identify ideas using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters, enabling users to screen thousands of securities to find ideas aligned with their own investment strategies.
Merck & Co., Inc. is a global biopharmaceutical leader whose market position is built on oncology, vaccines, and animal health. Its deep research capabilities, blockbuster product portfolio, and worldwide commercial reach make it a closely watched name in the healthcare sector. At the same time, its reliance on Keytruda and exposure to pricing and regulatory changes mean that understanding both its strengths and its risks is essential for anyone evaluating MRK.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of human and animal health products
Industry PharmaceuticalsMajor